We are thrilled to announce that MindMed has been included in the Russell 2000 Index and the broad-market Russell 3000 Index. The Russell 3000 Index features the 3,000 largest U.S.-traded stocks based on market-capitalization rankings and style attributes. businesswire.com/news/home/2024…

Psychedelic research is moving at an outstanding pace - and sometimes it's hard to keep up! Our CMO, Dan Karlin answers questions such as, "What is FDA breakthrough designation?" and more. Watch the video here: hcplive.com/view/daniel-ka…

According to Psychology Today, 30% of adults in North America experience anxiety, but only 1/3 of them are properly diagnosed. Both awareness and diagnosis are vital for better mental health care. Which of the following can be symptoms of GAD? (Check back next week for the answer!)

It's official! We're happy to announce a new patent covering the pharmaceutical formulation for our MM120 Orally Disintegrating Tablet (ODT). This extends our IP protection for MM120 through 2041. Read the full Press Release here: ir.mindmed.co/news-events/pr…

If you guessed "All of the above", you're right! GAD can manifest in ways that might seem unrelated. If you're experiencing the above symptoms, excessive worry, fatigue, irritability, or muscle tension, consider speaking to a mental health professional.

1950 - 1960 Psychedelic research blossomed to reveal innovative approaches to psychedelic treatments. As we build upon this history, we're shaping a brighter future for mental health care, with innovative treatments that offer hope and healing to individuals worldwide.

We welcome Stephanie Fagan to the MindMed team as Chief Corporate Affairs Officer. With over 20 years of experience as an executive in the healthcare industry, Stephanie Fagan will serve as an executive team member, overseeing public affairs and corporate communications.

"Our mission at MindMed is to push the boundaries of mental health treatment. We believe in the potential of psychedelics to transform lives and bring hope to those with GAD." - Rob Barrow, CEO. We aim to address the root causes of mental health conditions, not just symptoms.

MindMed will participate in the Canaccord Genuity Growth Conference, a prestigious event that joins institutional investors worldwide. We look forward to connecting with industry leaders and investors about our advancements and commitment to shaping the future of mental health.

We are in the running for a panel at @SXSW 25, and we need your help! "Understanding Anxiety Inside Out – Beyond the Emotions," will take inspiration from the movie Inside Out 2 to explore anxiety from a new perspective. 🗳️ Every vote counts! panelpicker.sxsw.com/vote/152525

MindMed reported Second Quarter 2024 financial results and business updates. For full details, read the Press Release here: ir.mindmed.co/news-events/pr…

GAD is highly prevalent yet underdiagnosed, leading to undertreatment and economic impacts. MindMed's research shows healthcare resource use in GAD patients, including medical visits, medications, and hospital admissions. We aim to improve outcomes with targeted interventions.

Neuroplasticity is the change that occurs in our brains as we form memories, habits and skills. This adaptability allows the brain to create, organize and reorganize connections. Psychedelics may enhance connectivity, potentially reversing negative changes from past experiences.